Attention Deficit Hyperactivity Disorder Market Size, Share & Trends Analysis Report By Drug Type (Stimulants, Non-stimulants), By Demographics (Children, Adults), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
Attention Deficit Hyperactivity Disorder Market Growth & Trends
The global attention deficit hyperactivity disorder market size is expected to reach USD 18.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.7% from 2024 to 2030. The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.
Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.
Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.
However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.
Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.
Attention Deficit Hyperactivity Disorder Market Report Highlights
Attention Deficit Hyperactivity Disorder Market Growth & Trends
The global attention deficit hyperactivity disorder market size is expected to reach USD 18.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.7% from 2024 to 2030. The presence of a strong product pipeline for the treatment of ADHD and their subsequent approval is expected to boost the market growth. Some late-stage pipeline products are NRCT-101 developed by Neurocentria, Inc., SPN-812 by Supernus Pharmaceuticals, Inc., and EB-1020 by Otsuka America Pharmaceutical, Inc.
Several initiatives undertaken by government bodies regarding early diagnosis and treatment of ADHD are likely to support the market growth. In January 2021, the Australian Government included Vyvanse under its Pharmaceutical Benefits Scheme (PBS) for the treatment of adult patients with ADHD. This inclusion makes the availability of Vyvanse at a subsidized rate to patients and more than 20,000 patients received a comparable treatment for the disease at low cost and benefits. Without PBS subsidy, the patients had to pay more than USD 1,200 per person annually for their treatment. After the inclusion in PBS, they will receive the treatment at USD 41.30 per script. Such initiatives are also expected to drive market growth.
Increasing awareness about ADHD among patients, physicians, and other healthcare providers may increase the demand for diagnosis and treatment which in turn propel the growth of the attention deficit hyperactivity disorder market. The Attention Deficit Hyperactivity Disorder Coaches Organization (ACO) celebrates October as the ADHD awareness month intending to raise awareness, generate funding for R&D, and educate people about disorders. This initiative may boost early diagnosis, thereby, increasing product penetration.
However, the risk of comorbidity with other psychiatric disorders is high among children with ADHD, often making diagnosis and treatment of the disorder complex. A research study published by the Lundbeck Foundation in 2021 showed that ADHD patients with other psychiatric comorbid conditions were more likely to avoid taking medicines. Some of the comorbid conditions that typically occur in ADHD pediatric patients are depression, anxiety, bipolar disorder, learning disorder, early speech/communication problems, and oppositional defiant disorder.
Furthermore, the shortage of stimulants to treat ADHD has forced patients to pay for expensive branded medication and create scope for substitute therapies, such as behavioral therapy, which will negatively impact the demand for ADHD pharmacological therapies. Strict regulations are implemented by regulatory bodies, such as the U.S. Drug Enforcement Administration (DEA), which limit the production of ADHD drugs to avoid misuse or abuse. Amid an increase in demand, this can create a shortage of medical products, consequently increasing the cost of treatments and restraining market growth. Thus, the shortage of medicines may impede the market growth.
Attention Deficit Hyperactivity Disorder Market Report Highlights
- By drug type, the stimulants segment accounted for the largest share of the market in 2023 due to the high demand for these medicines and the management of symptoms, government support for the use of stimulants drugs, and continuing clinical trials regarding attention deficit hyperactive disorder
- Based on demographics, the adults segment dominated the attention-deficit hyperactivity disorder market in 2023 owing to the large target population base and high risk of developing the attention-deficit hyperactive disorder. According to ADD Health and Wellness Centers, Inc. the disorder affects approximately 4-5% of the adult population
- Retail pharmacy segment dominated the attention-deficit hyperactivity disorder market in 2023 and is anticipated to witness the fastest growth over the forecast period. This can be attributed to the wide availability of attention deficit hyperactivity disorder drugs at retail pharmacies and their ease of accessibility to patients
- North America dominated the global market in 2023 owing to factors such as high awareness among healthcare professionals about drugs available for treatment and the rise in disease prevalence. According to the Center for ADHD Awareness Canada (CADDAC), more than 1.5 million people are affected by the disease in Canad
- Asia Pacific is expected to be the fastest-growing region during the forecast period to increasing ADHD prevalence and treatment demand in the region. For instance, ADHD is one of the most common neurodevelopment diseases with approximately 8.2% of children and 11% of boys diagnosed in Australia
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug type
1.2.2. Demographics
1.2.3. Distribution channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. CHAPTER 2 EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. Demographics outlook
2.2.3. Distribution channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of ADHD
3.2.1.2. Increasing awareness about ADHD Among Physicians And Patients
3.2.2. Market restraint analysis
3.2.2.1. Shortage of ADHD drugs
3.2.2.2. Low availability of non-stimulant ADHD drugs
3.2.2.3. Comorbidities leading to underdiagnosis in children
3.3. Attention Deficit Hyperactivity Disorder Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
4.1. Drug Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Attention Deficit Hyperactivity Disorder Market by Drug Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Stimulants
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Amphetamine
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Methylphenidate
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Lisdexamfetamine
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Dexmethylphenidate
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Non stimulants
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Atomoxetine
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Guanfacine
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Clonidine
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.5. Others
4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DEMOGRAPHICS ESTIMATES & TREND ANALYSIS
5.1. Demographics Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Attention Deficit Hyperactivity Disorder Market by Demographics Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Children
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Adults
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Distribution Channel Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Attention Deficit Hyperactivity Disorder Market by Distribution Channel Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospital pharmacy
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Retail pharmacy
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. CHAPTER 8 COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Pfizer, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Johnson & Johnson Services, Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Lupin
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Novartis AG
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Takeda Pharmaceutical Company Limited
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Mallinckrodt plc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Purdue Pharma L.p
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Supernus Pharmaceuticals, Inc.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. NEOS Therapeutics, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. H.S. Hospital Service S.p.A.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug type
1.2.2. Demographics
1.2.3. Distribution channel
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. CHAPTER 2 EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug type outlook
2.2.2. Demographics outlook
2.2.3. Distribution channel outlook
2.2.4. Regional outlook
2.3. Competitive Insights
CHAPTER 3. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of ADHD
3.2.1.2. Increasing awareness about ADHD Among Physicians And Patients
3.2.2. Market restraint analysis
3.2.2.1. Shortage of ADHD drugs
3.2.2.2. Low availability of non-stimulant ADHD drugs
3.2.2.3. Comorbidities leading to underdiagnosis in children
3.3. Attention Deficit Hyperactivity Disorder Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
4.1. Drug Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Attention Deficit Hyperactivity Disorder Market by Drug Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. Stimulants
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Amphetamine
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Methylphenidate
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Lisdexamfetamine
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Dexmethylphenidate
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Non stimulants
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Atomoxetine
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Guanfacine
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Clonidine
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.5. Others
4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DEMOGRAPHICS ESTIMATES & TREND ANALYSIS
5.1. Demographics Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Attention Deficit Hyperactivity Disorder Market by Demographics Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Children
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Adults
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Distribution Channel Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Attention Deficit Hyperactivity Disorder Market by Distribution Channel Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospital pharmacy
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Retail pharmacy
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. ATTENTION DEFICIT HYPERACTIVITY DISORDER MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/ reimbursement structure
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/ reimbursement structure
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/ reimbursement structure
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Norway
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/ reimbursement structure
7.6.6.3. Competitive scenario
7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/ reimbursement structure
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Denmark
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/ reimbursement structure
7.6.8.3. Competitive scenario
7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. South Korea
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/ reimbursement structure
7.7.5.3. Competitive scenario
7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. Thailand
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/ reimbursement structure
7.7.6.3. Competitive scenario
7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework/ reimbursement structure
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/ reimbursement structure
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/ reimbursement structure
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework/ reimbursement structure
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/ reimbursement structure
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/ reimbursement structure
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/ reimbursement structure
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. CHAPTER 8 COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Pfizer, Inc.
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Johnson & Johnson Services, Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Lupin
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Novartis AG
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Takeda Pharmaceutical Company Limited
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Mallinckrodt plc.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Purdue Pharma L.p
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Supernus Pharmaceuticals, Inc.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. NEOS Therapeutics, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. H.S. Hospital Service S.p.A.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 North America attention deficit hyperactivity disorder market, 2018 - 2030 (USD Million)
Table 3 North America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 5 North America attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 7 U.S. attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 8 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 10 Canada attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 11 Canada attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 13 Europe attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 14 Europe attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 15 Europe attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Germany attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 17 Germany attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 18 Germany attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 UK attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 20 UK attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 21 UK attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 23 France attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 24 France attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 26 Italy attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 27 Italy attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 29 Spain attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 30 Spain attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Denmark attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 32 Denmark attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 33 Denmark attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Sweden attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 35 Sweden attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 36 Sweden attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Norway attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 38 Norway attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 39 Norway attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 43 Asia Pacific attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 Japan attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 45 Japan attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 46 Japan attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 China attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 48 China attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 49 China attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 51 India attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 52 India attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 South Korea attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 54 South Korea attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 55 South Korea attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Australia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 57 Australia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 58 Australia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Thailand attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 60 Thailand attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 61 Thailand attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 64 Latin America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 65 Latin America attention deficit hyperactivity disorder n market, by distribution channel, 2018 - 2030 (USD Million)
Table 66 Brazil attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 67 Brazil attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 68 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 70 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Mexico attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 73 Mexico attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 74 Mexico attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 Argentina attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 76 Argentina attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 77 Argentina attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 MEA Attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 79 MEA attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 80 MEA attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 81 MEA attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 South Africa attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 83 South Africa attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 84 South Africa attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 UAE attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 89 UAE attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 90 UAE attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Kuwait attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 92 Kuwait attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 93 Kuwait attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 North America attention deficit hyperactivity disorder market, 2018 - 2030 (USD Million)
Table 3 North America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 4 North America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 5 North America attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 6 U.S. attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 7 U.S. attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 8 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 9 Canada attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 10 Canada attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 11 Canada attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 12 Europe attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 13 Europe attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 14 Europe attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 15 Europe attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 16 Germany attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 17 Germany attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 18 Germany attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 19 UK attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 20 UK attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 21 UK attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 22 France attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 23 France attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 24 France attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Italy attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 26 Italy attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 27 Italy attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 28 Spain attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 29 Spain attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 30 Spain attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 31 Denmark attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 32 Denmark attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 33 Denmark attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 34 Sweden attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 35 Sweden attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 36 Sweden attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Norway attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 38 Norway attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 39 Norway attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 40 Asia Pacific attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 41 Asia Pacific attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 42 Asia Pacific attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 43 Asia Pacific attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 44 Japan attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 45 Japan attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 46 Japan attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 47 China attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 48 China attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 49 China attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 50 India attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 51 India attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 52 India attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 South Korea attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 54 South Korea attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 55 South Korea attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 56 Australia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 57 Australia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 58 Australia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 59 Thailand attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 60 Thailand attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 61 Thailand attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 62 Latin America attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 63 Latin America attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 64 Latin America attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 65 Latin America attention deficit hyperactivity disorder n market, by distribution channel, 2018 - 2030 (USD Million)
Table 66 Brazil attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 67 Brazil attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 68 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 69 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 70 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 71 Brazil attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 72 Mexico attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 73 Mexico attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 74 Mexico attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 75 Argentina attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 76 Argentina attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 77 Argentina attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 78 MEA Attention deficit hyperactivity disorder market, by region, 2018 - 2030 (USD Million)
Table 79 MEA attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 80 MEA attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 81 MEA attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 82 South Africa attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 83 South Africa attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 84 South Africa attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 85 Saudi Arabia attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 86 Saudi Arabia attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 87 Saudi Arabia attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 88 UAE attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 89 UAE attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 90 UAE attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
Table 91 Kuwait attention deficit hyperactivity disorder market, by drug type, 2018 - 2030 (USD Million)
Table 92 Kuwait attention deficit hyperactivity disorder market, by demographics, 2018 - 2030 (USD Million)
Table 93 Kuwait attention deficit hyperactivity disorder market, by distribution channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Attention deficit hyperactivity disorder market: Market outlook
Fig. 9 Attention deficit hyperactivity disorder market: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Attention deficit hyperactivity disorder market driver impact
Fig. 14 Attention deficit hyperactivity disorder market restraint impact
Fig. 15 Attention deficit hyperactivity disorder market: Drug type movement analysis
Fig. 16 Attention deficit hyperactivity disorder market: Drug type outlook and key takeaways
Fig. 17 Stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Amphetamine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Methylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Lisdexamfetamine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Dexmethylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Non-stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Atomoxetine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Guanfacine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Clonidine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Attention deficit hyperactivity disorder Market: Demographics movement Analysis
Fig. 28 Attention deficit hyperactivity disorder market: Demographics outlook and key takeaways
Fig. 29 Children market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Attention deficit hyperactivity disorder market: Distribution channel movement analysis
Fig. 32 Attention deficit hyperactivity disorder market: Distribution channel outlook and key takeaways
Fig. 33 Hospital pharmacy; market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Global attention deficit hyperactivity disorder market: Regional movement analysis
Fig. 36 Global attention deficit hyperactivity disorder market: Regional outlook and key takeaways
Fig. 37 North America
Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 U.S.
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Canada
Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe
Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 UK
Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Germany
Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 France
Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Italy
Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Spain
Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Denmark
Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Sweden
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Norway
Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific
Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Japan
Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China
Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 India
Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 South Korea
Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Australia
Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Thailand
Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Latin America
Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Brazil
Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Mexico
Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Argentina
Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Middle East and Africa
Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 South Africa
Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Saudi Arabia
Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 UAE
Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Kuwait
Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Attention deficit hyperactivity disorder market: Market outlook
Fig. 9 Attention deficit hyperactivity disorder market: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Attention deficit hyperactivity disorder market driver impact
Fig. 14 Attention deficit hyperactivity disorder market restraint impact
Fig. 15 Attention deficit hyperactivity disorder market: Drug type movement analysis
Fig. 16 Attention deficit hyperactivity disorder market: Drug type outlook and key takeaways
Fig. 17 Stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Amphetamine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Methylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Lisdexamfetamine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Dexmethylphenidate market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Non-stimulants market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Atomoxetine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Guanfacine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Clonidine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Attention deficit hyperactivity disorder Market: Demographics movement Analysis
Fig. 28 Attention deficit hyperactivity disorder market: Demographics outlook and key takeaways
Fig. 29 Children market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Adults market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Attention deficit hyperactivity disorder market: Distribution channel movement analysis
Fig. 32 Attention deficit hyperactivity disorder market: Distribution channel outlook and key takeaways
Fig. 33 Hospital pharmacy; market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Retail pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Global attention deficit hyperactivity disorder market: Regional movement analysis
Fig. 36 Global attention deficit hyperactivity disorder market: Regional outlook and key takeaways
Fig. 37 North America
Fig. 38 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 U.S.
Fig. 40 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Canada
Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe
Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 UK
Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Germany
Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 France
Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Italy
Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Spain
Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Denmark
Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Sweden
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Norway
Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Asia Pacific
Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Japan
Fig. 64 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 China
Fig. 66 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 India
Fig. 68 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 South Korea
Fig. 70 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Australia
Fig. 72 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Thailand
Fig. 74 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Latin America
Fig. 76 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Brazil
Fig. 78 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Mexico
Fig. 80 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Argentina
Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Middle East and Africa
Fig. 84 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 85 South Africa
Fig. 86 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Saudi Arabia
Fig. 88 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 UAE
Fig. 90 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Kuwait
Fig. 92 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
